Our History


Mediolanum Farmaceutici was born


Mediolanum Farmaceutici invested in pharmaceutical research and started the production of its first original and patented molecules


The first product of the R&D of the company was commercialized


The international expansion project started with the opening of the first French branch. Through some patent agreements, the commercialization of some successful cardiovascular products was initialized (statins, ACE-inhibitors)


The two companies Istituto Gentili e Neopharmed were acquired by MSD


Vamfarma, the third production site of Mediolanum, was inaugurated in Comazzo (Lodi), to support the Leurquin site and the Research and Production Unity for the subcutaneous drugging devices. The three production sites together turned Mediolanum into a pharmaceutical workshop both in Italy and France


Acquisition of the Therabel Gienne Pharma, the Italian branch of the Dutch Group Therabel


The agreement with Novartis Oncology started the building of the new Istituto Gentili’s reality, fully designated to oncology, which became the Italian supplier of the Tyverb® (lapatinib), the innovative drug suggested for the treatment of the mammary carcinoma HER2-positive


The majority of the Neopharmed Gentili was sold to an investment fund; it was born from the hiving off of some of the Group’s assets as the respiratory, the cardiovascular and the pain ones


Acquisition of the products of the OncoCare of Teva Italy, which further strengthened the effort in oncology


The Diomede company is established with the aim of acquiring and renovating properties.


Acquisition of the French biotech ElsaLys for the development of advanced immuno-oncological therapies


Acquisition, by the Istituto Gentili, of the aromatase inhibitors portfolio along with a product designated to the support of the oncological patient, which further expanded the answer of the company to the fight against breast cancer

Il tuo browser non è aggiornato!

Aggiornalo per vedere questo sito correttamente.